BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer

Ruoshi Shi, Sebastião N. Martins Filho, Ming Li, Aline Fusco Fares, Jessica Weiss, Nhu‐An Pham, Olga Ludkovski, Vibha Raghavan, Quan Li, D. Ravi, Michael Cabanero, Nadeem Moghal, Natasha B. Leighl, Penelope A. Bradbury, Adrian G. Sacher, Frances A. Shepherd, Kazuhiro Yasufuku, Ming‐Sound Tsao, Geoffrey Liu